NCT00437372View on ClinicalTrials.gov

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
CancerHead and Neck CancerPelvic CancerNervous System NeoplasmsThoracic Neoplasms
Interventions
DRUG

Sunitinib

"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."

RADIATION

External Beam Radiation Therapy

Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT00437372 - Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients | Biotech Hunter | Biotech Hunter